Replies to post #115157 on Biotech Values

[DewDiligence]

I also like the fact that ACH-2684, due to enter the clinic shortly, is apparently the only other PI either in the clinic or about to enter the clinic, other than the MRK PI in Phase 1, that's active against HCV genotype 3.

I’m not sure this is true. For instance, GILD has a PI in phase-1 but has not yet disclosed any details to investors.